Rate Video

ASH 2014 | Recent investigational advances in the management of relapsed/refractory myeloma

Paul Richardson • 6 Dec 2014

Multiple Myeloma Antibodies Carfilzomib Daratumumab Elotuzumab Panobinostat Pomalidomide Ricolinostat

Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple myeloma presented at the 2014 American Society of Hematology (ASH) Annual Meeting.

Investigational agents discussed include: proteasome inhibitor, carfilzomib; anti-CD38 monoclonal antibody, daratumumab: anti-SLAMF7 monoclonal antibody, elotuzumab; histone deacetylase (HDAC) inhibitor, panobinostat; HDAC6 inhibitor, ricolinostat; immunomodulatory agent, pomalidomide.

Updates on defibrotide therapy

Paul Richardson • 15 Jun 2019

Isatuximab: a ‘next-generation monoclonal antibody’

Paul Richardson • 14 Jun 2018

GRIFFIN updates: D-RVd vs RVd in transplant-eligible patients with newly diagnosed multiple myeloma

Paul Richardson • 12 Dec 2021

Recent drug approvals for the treatment of relapsed/refractory multiple myeloma

Paul Richardson • 18 Apr 2016

Related Videos

PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma

Adam Sperling • 13 Jun 2022

Dual-targeting BCMA/CD19 CAR-T therapy in patients with R/R MM

Juan Du • 13 Jun 2022

The association between prior exposure to lenalidomide and TP53-mutated AML/MDS

Adam Sperling • 13 Jun 2022

Updates in immunotherapy for multiple myeloma: BiTEs & novel targets

Adam Sperling • 13 Jun 2022